Selected article for: "immune response and retrospective study"

Author: Notz, Quirin; Herrmann, Johannes; Schlesinger, Tobias; Helmer, Philipp; Sudowe, Stephan; Sun, Qian; Hackler, Julian; Roeder, Daniel; Lotz, Christopher; Meybohm, Patrick; Kranke, Peter; Schomburg, Lutz; Stoppe, Christian
Title: Clinical Significance of Micronutrient Supplementation in Critically Ill COVID-19 Patients with Severe ARDS
  • Cord-id: 1e6zhkju
  • Document date: 2021_6_20
  • ID: 1e6zhkju
    Snippet: The interplay between inflammation and oxidative stress is a vicious circle, potentially resulting in organ damage. Essential micronutrients such as selenium (Se) and zinc (Zn) support anti-oxidative defense systems and are commonly depleted in severe disease. This single-center retrospective study investigated micronutrient levels under Se and Zn supplementation in critically ill patients with COVID-19 induced acute respiratory distress syndrome (ARDS) and explored potential relationships with
    Document: The interplay between inflammation and oxidative stress is a vicious circle, potentially resulting in organ damage. Essential micronutrients such as selenium (Se) and zinc (Zn) support anti-oxidative defense systems and are commonly depleted in severe disease. This single-center retrospective study investigated micronutrient levels under Se and Zn supplementation in critically ill patients with COVID-19 induced acute respiratory distress syndrome (ARDS) and explored potential relationships with immunological and clinical parameters. According to intensive care unit (ICU) standard operating procedures, patients received 1.0 mg of intravenous Se daily on top of artificial nutrition, which contained various amounts of Se and Zn. Micronutrients, inflammatory cytokines, lymphocyte subsets and clinical data were extracted from the patient data management system on admission and after 10 to 14 days of treatment. Forty-six patients were screened for eligibility and 22 patients were included in the study. Twenty-one patients (95%) suffered from severe ARDS and 14 patients (64%) survived to ICU discharge. On admission, the majority of patients had low Se status biomarkers and Zn levels, along with elevated inflammatory parameters. Se supplementation significantly elevated Se (p = 0.027) and selenoprotein P levels (SELENOP; p = 0.016) to normal range. Accordingly, glutathione peroxidase 3 (GPx3) activity increased over time (p = 0.021). Se biomarkers, most notably SELENOP, were inversely correlated with CRP (r(s) = −0.495), PCT (r(s) = −0.413), IL-6 (r(s) = −0.429), IL-1β (r(s) = −0.440) and IL-10 (r(s) = −0.461). Positive associations were found for CD8(+) T cells (r(s) = 0.636), NK cells (r(s) = 0.772), total IgG (r(s) = 0.493) and PaO(2)/FiO(2) ratios (r(s) = 0.504). In addition, survivors tended to have higher Se levels after 10 to 14 days compared to non-survivors (p = 0.075). Sufficient Se and Zn levels may potentially be of clinical significance for an adequate immune response in critically ill patients with severe COVID-19 ARDS.

    Search related documents:
    Co phrase search for related documents
    • absolute number and acute lung injury: 1
    • absolute number and adaptive innate: 1, 2, 3, 4
    • absolute number and lung injury: 1
    • absolute number and lymphocyte count: 1, 2, 3
    • absolute number and lymphocyte number: 1, 2, 3, 4, 5, 6, 7, 8
    • absolute number and lymphocyte subset: 1, 2
    • active site and acute ards respiratory distress syndrome: 1, 2
    • active site and acute lung injury: 1, 2
    • active site and adaptive innate: 1, 2
    • active site and additional insight: 1
    • active site and lung injury: 1, 2
    • acute ards respiratory distress syndrome and adaptive innate: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22
    • acute ards respiratory distress syndrome and adaptive innate immunity: 1, 2, 3, 4, 5
    • acute ards respiratory distress syndrome and additional patient: 1, 2
    • acute ards respiratory distress syndrome and additional trial: 1
    • acute ards respiratory distress syndrome and adenine nadph dinucleotide phosphate: 1
    • acute ards respiratory distress syndrome and adjuvant admission: 1
    • acute ards respiratory distress syndrome and lung injury: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75
    • acute ards respiratory distress syndrome and lymphocyte count: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37